These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14692521)

  • 41. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
    Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
    Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cutaneous lymphoma at the Dermatology Day conference, Paris 2010].
    Battistella M
    Ann Dermatol Venereol; 2011 May; 138(5 Suppl 2):H1-11. PubMed ID: 21703464
    [No Abstract]   [Full Text] [Related]  

  • 43. [Current approaches to diagnosing and treating primary cutaneous lymphomas on the basis of a new WHO-EORTC classification, cutaneous T-cell lymphomas].
    Belousova IE; Kazakov DV; Krivolapov IuA
    Arkh Patol; 2007; 69(5):11-7. PubMed ID: 18074813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
    Nikolova M; Bagot M; Boumsell L; Bensussan A
    Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
    Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
    J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
    Querfeld C; Kuzel TM; Guitart J; Rosen ST
    Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.
    Marshall JA; Forster TH; Purdie DM; Lanagan CM; O'Connor LE; O'Rourke MG; Johnson MK; See JL; Ellem KA; Martinez NR; López JA; Schmidt CW
    Immunol Cell Biol; 2006 Jun; 84(3):295-302. PubMed ID: 16681827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Malignant lymphoma of the skin].
    Burg G; Dommann S; Dummer R
    Ther Umsch; 1993 Dec; 50(12):828-34. PubMed ID: 8171405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A rare pediatric case of cutaneous gamma/delta T-cell lymphoma.
    Kerbout M; Mekouar F; Bahadi N; El Omri N; Assoufi N; El Qatni M; Mikdame M; Ghafir D
    Ann Biol Clin (Paris); 2014; 72(4):483-5. PubMed ID: 25119808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
    Ghazawi FM; Netchiporouk E; Rahme E; Tsang M; Moreau L; Glassman S; Provost N; Gilbert M; Jean SE; Pehr K; Sasseville D; Litvinov IV
    Cancer; 2017 Sep; 123(18):3550-3567. PubMed ID: 28493286
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope.
    Tumenjargal S; Gellrich S; Linnemann T; Muche JM; Lukowsky A; Audring H; Wiesmüller KH; Sterry W; Walden P
    Eur J Immunol; 2003 Nov; 33(11):3175-85. PubMed ID: 14579286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
    Klammer M; Roddie PH
    Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Dendritic cell-based cancer immunotherapy].
    Aruga A
    Nihon Rinsho; 2010 Jun; 68(6):1107-10. PubMed ID: 20535963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular biology techniques for the diagnosis of cutaneous T-cell lymphoma.
    Wood GS; Haeffner A; Dummer R; Crooks CF
    Dermatol Clin; 1994 Apr; 12(2):231-41. PubMed ID: 8045035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with a CD15(+)CD30(-) phenotype.
    Yoshizawa N; Yagi H; Horibe T; Takigawa M; Sugiura M
    Eur J Dermatol; 2007; 17(5):441-2. PubMed ID: 17673391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.
    Gormley RH; Hess SD; Anand D; Junkins-Hopkins J; Rook AH; Kim EJ
    J Am Acad Dermatol; 2010 Feb; 62(2):300-7. PubMed ID: 19944484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
    Paulli M; Berti E
    Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation.
    Nofal A; Abdel-Mawla MY; Assaf M; Salah E
    J Am Acad Dermatol; 2012 Oct; 67(4):748-59. PubMed ID: 22226429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma with a chronic and indolent course. Is this different from peripheral T cell lymphoma?
    Gomez Vazquez M; Navarra Amayuelas R
    Dermatol Online J; 2012 Mar; 18(3):11. PubMed ID: 22483522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.